{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:25:51Z","timestamp":1770071151517,"version":"3.49.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine relationships between radiographic progression and achievement of low disease activity (LDA) or remission at week 104 in patients with PsA receiving secukinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc analysis included data from patients with active PsA enrolled in the phase 3 FUTURE 5 study (NCT02404350). Patients were pooled by treatment received at week 104 (secukinumab 300\u2009mg with loading dose [LD], secukinumab 150\u2009mg with LD or secukinumab 150\u2009mg without LD) and grouped by radiographic progression status. Radiographic progression was defined as change from baseline to week 104 in van der Heijde modified Total Sharp Score &amp;gt;0.5. Efficacy was assessed by achievement of minimal disease activity (MDA), very low disease activity (VLDA) and Disease Activity Index for PsA (DAPSA) LDA or remission. Demographics and clinical characteristics associated with radiographic progression at week 104 were identified by logistic regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 541 patients included in this analysis, 457 (84.5%) were radiographic non-progressors and 84 (15.5%) were radiographic progressors. Higher proportions of non-progressors achieved MDA, VLDA and DAPSA LDA and remission at week 104 than progressors. Radiographic progression at week 104 was associated with older age and higher baseline high-sensitivity CRP level, whereas non-progression was associated with 300\u2009mg secukinumab (vs 150\u2009mg secukinumab without LD), no prior exposure to tumour necrosis factor inhibitors and lower BMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients without radiographic progression through 2\u2009years of secukinumab treatment had greater achievement of LDA states at week 104 than patients with radiographic progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov; NCT02404350.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf488","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:34:32Z","timestamp":1758022472000},"source":"Crossref","is-referenced-by-count":0,"title":["Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2\u2009years"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"first","affiliation":[{"name":"Swedish Medical Center\/Providence St. Joseph Health and University of Washington , Seattle, WA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine","family":"Gaillez","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Shew","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibin","family":"Bao","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher T","family":"Ritchlin","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center , Rochester, NY,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"2026020205384761100_keaf488-B1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020205384761100_keaf488-B2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40265-021-01476-3","article-title":"Secukinumab: a review in psoriatic arthritis","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"2026020205384761100_keaf488-B3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13075-020-2103-8","article-title":"Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research","volume":"22","author":"van der Heijde","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2026020205384761100_keaf488-B4","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1136\/annrheumdis-2017-211433","article-title":"The effects of structural damage on functional disability in psoriatic arthritis","volume":"76","author":"Kerschbaumer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026020205384761100_keaf488-B5","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3899\/jrheum.081015","article-title":"Spondyloarthritis is associated with poor function and physical health-related quality of life","volume":"36","author":"Singh","year":"2009","journal-title":"J Rheumatol"},{"key":"2026020205384761100_keaf488-B6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026020205384761100_keaf488-B7","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026020205384761100_keaf488-B8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/2040622315582354","article-title":"Psoriatic arthritis: latest treatments and their place in therapy","volume":"6","author":"Kang","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"key":"2026020205384761100_keaf488-B9","doi-asserted-by":"crossref","first-page":"1759720X221092376","DOI":"10.1177\/1759720X221092376","article-title":"Is there still a place for methotrexate in severe psoriatic arthritis?","volume":"14","author":"Felten","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026020205384761100_keaf488-B10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"2026020205384761100_keaf488-B11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"2026020205384761100_keaf488-B12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2026020205384761100_keaf488-B13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2026020205384761100_keaf488-B14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026020205384761100_keaf488-B15","doi-asserted-by":"crossref","first-page":"e001600","DOI":"10.1136\/rmdopen-2021-001600","article-title":"Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study","volume":"7","author":"Mease","year":"2021","journal-title":"RMD Open"},{"key":"2026020205384761100_keaf488-B16","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026020205384761100_keaf488-B17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2021-eular.1971","article-title":"POS1051 Secukinumab improves physical function and inhibits structural damage in PsA patients with sustained remission or low disease activity: results from a phase 3 study","volume":"80","author":"Coates","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026020205384761100_keaf488-B18","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205384761100_keaf488-B19","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death","volume":"41","author":"Gladman","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2026020205384761100_keaf488-B20","doi-asserted-by":"crossref","first-page":"e002789","DOI":"10.1136\/rmdopen-2022-002789","article-title":"Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naive patients with active psoriatic arthritis","volume":"9","author":"Gottlieb","year":"2023","journal-title":"RMD Open"},{"key":"2026020205384761100_keaf488-B21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.23345","article-title":"Radiographic progression in psoriatic arthritis achieving a good response to treatment: data using newer composite indices of disease activity","volume":"70","author":"Helliwell","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020205384761100_keaf488-B22","first-page":"758","article-title":"FRI0333 achievement of very low disease activity and remission treatment targets is associated with reduced radiographic progression in patients with psoriatic arthritis treated with certolizumab pegol","volume":"79","author":"Coates","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026020205384761100_keaf488-B23","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3899\/jrheum.140172","article-title":"Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response","volume":"41","author":"Helliwell","year":"2014","journal-title":"J Rheumatol"},{"key":"2026020205384761100_keaf488-B24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s13075-022-02944-1","article-title":"Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis","volume":"24","author":"Mease","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026020205384761100_keaf488-B25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/ard-2022-222787","article-title":"Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis","volume":"82","author":"Gessl","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026020205384761100_keaf488-B26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard.2006.056457","article-title":"Predictors for radiological damage in psoriatic arthritis: results from a single centre","volume":"66","author":"Bond","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2026020205384761100_keaf488-B27","doi-asserted-by":"crossref","first-page":"e004080","DOI":"10.1136\/rmdopen-2024-004080","article-title":"Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort","volume":"10","author":"Koc","year":"2024","journal-title":"RMD Open"},{"key":"2026020205384761100_keaf488-B28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.55563\/clinexprheumatol\/ic89a8","article-title":"Secukinumab\u2019s effect on structural damage progression in psoriatic arthritis: longitudinal mixture modelling of FUTURE-1 and FUTURE-5","volume":"39","author":"Luttringer","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2026020205384761100_keaf488-B29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3899\/jrheum.180971","article-title":"Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or adalimumab","volume":"46","author":"van der Heijde","year":"2019","journal-title":"J Rheumatol"},{"key":"2026020205384761100_keaf488-B30","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1186\/ar3049","article-title":"Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT","volume":"12","author":"Gladman","year":"2010","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf488\/64318733\/keaf488.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf488\/64318733\/keaf488.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf488\/64318733\/keaf488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:38:57Z","timestamp":1770028737000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf488\/8257827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf488","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,18]]},"article-number":"keaf488"}}